icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
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
KsKq8veXWvqQw1XY